STOCK TITAN

MVE Biological Solutions, A Cryoport Company, Introduces Real-Time Integrated Condition Monitoring Systems For Cryogenic Dewars

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

MVE Biological Solutions (NASDAQ: CYRX) unveiled integrated real-time condition monitoring for its MVE SC 4/2 V and 4/3 V cryogenic dewars on Oct 7, 2025. The systems embed SmartTag (LTE, up to 120 days battery) or CryoBeacon (BLE 5.0, logs to –200°C plus ambient humidity) into dewar lids and stream data to MVECloud, an FDA 21 CFR Part 11 and GAMP 5 compliant web/mobile platform offering visibility, real-time alerts, QR-based data retrieval, and reporting.

The launch positions MVE to offer connected assets for shipments and stationary storage and to pursue services and potential subscription-based revenue as part of Cryoport's broader monitoring strategy.

MVE Biological Solutions (NASDAQ: CYRX) ha presentato il monitoraggio integrato in tempo reale delle condizioni per i dewar criogenici MVE SC 4/2 V e 4/3 V il 7 ottobre 2025. I sistemi incorporano SmartTag (LTE, batteria fino a 120 giorni) o CryoBeacon (BLE 5.0, registra dati fino a –200°C e umidità ambiente) nelle coperchi dei dewar e trasmettono i dati a MVECloud, una piattaforma web/mobile compatibile con FDA 21 CFR Part 11 e GAMP 5 che offre visibilità, avvisi in tempo reale, recupero dati tramite QR e reporting.

Il lancio posiziona MVE per offrire asset connessi per spedizioni e storage stationary e per perseguire servizi e potenziali introiti basati su abbonamento come parte della strategia di monitoraggio più ampia di Cryoport.

MVE Biological Solutions (NASDAQ: CYRX) presentó la monitorización integrada en tiempo real de las condiciones para los dewars criogénicos MVE SC 4/2 V y 4/3 V el 7 de octubre de 2025. Los sistemas incrustan SmartTag (LTE, batería de hasta 120 días) o CryoBeacon (BLE 5.0, registra datos hasta –200 °C y humedad ambiental) en las tapas de los dewars y transmiten datos a MVECloud, una plataforma web/móvil compatible con FDA 21 CFR Part 11 y GAMP 5 que ofrece visibilidad, alertas en tiempo real, recuperación de datos mediante código QR y generación de informes.

El lanzamiento sitúa a MVE para ofrecer activos conectados para envíos y almacenamiento estacionario y buscar servicios y ingresos potenciales por suscripción como parte de la estrategia de monitoreo más amplia de Cryoport.

MVE Biological Solutions (NASDAQ: CYRX)는 2025년 10월 7일 MVE SC 4/2 V4/3 V 초저온 보관용 Dewar의 실시간 상태 모니터링을 도입했습니다. 이 시스템은 뚜껑에 SmartTag (LTE, 최대 120일 배터리) 또는 CryoBeacon (BLE 5.0, –200°C까지 기록 및 주변 습도)를 내장하고 데이터를 MVECloud로 스트리밍합니다. MVECloud는 FDA 21 CFR Part 11 및 GAMP 5를 준수하는 웹/모바일 플랫폼으로 가시성, 실시간 알림, QR 기반 데이터 검색 및 보고를 제공합니다.

이런 출시로 MVE는 선적용 자산과 고정 저장 자산에 대한 연결성을 제공하고 Cryoport의 더 넓은 모니터링 전략의 일부로 서비스 및 구독 기반 매출을 추구하게 됩니다.

MVE Biological Solutions (NASDAQ: CYRX) a dévoilé le suivi intégré en temps réel des conditions pour ses Dewars cryogéniques MVE SC 4/2 V et 4/3 V le 7 octobre 2025. Les systèmes intègrent SmartTag (LTE, batterie jusqu'à 120 jours) ou CryoBeacon (BLE 5.0, enregistre jusqu'à –200 °C et l'humidité ambiante) dans les couvercles des dewars et envoient les données vers MVECloud, une plateforme web/mobile conforme FDA 21 CFR Part 11 et GAMP 5 offrant visibilité, alertes en temps réel, récupération des données via QR et reporting.

Ce lancement positionne MVE pour proposer des actifs connectés pour les expéditions et le stockage stationnaire et poursuivre des services et des revenus potentiels basés sur l'abonnement dans le cadre de la stratégie de monitoring plus large de Cryoport.

MVE Biological Solutions (NASDAQ: CYRX) hat am 7. Oktober 2025 eine integrierte Echtzeit-Statusüberwachung für seine kryogenen Dewars MVE SC 4/2 V und 4/3 V vorgestellt. Die Systeme integrieren SmartTag (LTE, bis zu 120 Tage Batterie) oder CryoBeacon (BLE 5.0, protokolliert bis –200 °C sowie Umgebungsfeuchtigkeit) in die Dewar-Deckel und streamen Daten an MVECloud, eine FDA 21 CFR Part 11 und GAMP 5 konforme Web-/Mobile-Plattform, die Transparenz, Echtzeit-Warnungen, QR-basierte Datenerfassung und Reporting bietet.

Der Launch positioniert MVE, vernetzte Vermögenswerte für Versand und stationäre Lagerung anzubieten und Services und potenzielle abonnementbasierte Einnahmen im Rahmen der umfassenderen Monitoring-Strategie von Cryoport zu verfolgen.

MVE Biological Solutions (NASDAQ: CYRX) كشفت عن رصد حالة متكامل في الوقت الفعلي للدواير التخزينية بالتبريد MVE SC 4/2 V و 4/3 V في 7 أكتوبر 2025. تدمج الأنظمة SmartTag (LTE، بطارية حتى 120 يوماً) أو CryoBeacon (BLE 5.0، يسجل حتى –200°C بالإضافة إلى الرطوبة المحيطة) في أغطية الدواير وبث البيانات إلى MVECloud، وهي منصة ويب/الهاتف المحمول متوافقة مع FDA 21 CFR Part 11 وGAMP 5 وتوفر الرؤية، التنبيهات في الوقت الفعلي، استرداد البيانات عبر QR والتقارير.

يضع الإصدار الجديد MVE في موقع يمكنه من تقديم أصول متصلة للشحن والتخزين الثابت والسعي نحو خدمات وإيرادات محتملة قائمة على الاشتراك كجزء من إستراتيجية المراقبة الأوسع لشركة Cryoport.

MVE Biological Solutions (NASDAQ: CYRX) 于 2025 年 10 月 7 日推出其 MVE SC 4/2 V4/3 V 短期低温储存用 Dewar 的集成实时状态监测。系统在 Dewar 瓶盖中内嵌 SmartTag(LTE,电池可达 120 天)或 CryoBeacon(BLE 5.0,记录至 –200°C 及环境湿度),并将数据流式传输到 MVECloud,该平台符合 FDA 21 CFR Part 11 与 GAMP 5 的网络/移动端合规要求,提供可视性、实时警报、基于 QR 的数据检索与报告功能。

此次发布使 MVE 能为运输和静态存储提供连接资产,并在 Cryoport 更广泛的监控战略框架内寻求服务与潜在的基于订阅的收入来源。

Positive
  • None.
Negative
  • None.

Insights

MVE added embedded BLE and LTE monitoring to dewars and a compliant cloud platform, positioning for subscription services.

Combining built-in SmartTag (LTE, ~120-day battery) and CryoBeacon (BLE 5.0, logs to –200°C) with the FDA 21 CFR Part 11 and GAMP 5 compliant MVECloud creates an integrated product+service offering. The integrated devices provide continuous or on‑demand temperature, humidity and ambient data and QR-based retrieval, converting physical dewars into connected assets that deliver centralized visibility and real-time alerts.

Key dependencies and risks include successful customer adoption of embedded telemetry, device reliability at cryogenic temperatures, and secure cloud operations consistent with regulatory compliance. The statement that this capability "lays the foundation for more connected, comprehensive monitoring" ties future commercial upside to converting hardware sales into subscription-based revenue, which requires scalable service delivery and clear pricing/contracting.

Concrete items to watch: uptake and pricing of the announced subscription services, the pace of embedding SmartTag/CryoBeacon across the MVE product line, and operational metrics around device uptime and data integrity. Near-term signals will be product shipments with integrated tags and initial service enrollments; medium-term signals will be recurring revenue reports and customer case examples.

Connected, Intelligent Condition Monitoring Assets that Safeguard Vital Life Science Materials Mark MVE's First Step in its Real-Time Integrated Systems Evolution

NASHVILLE, Tenn., Oct. 7, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX), a global leader in supply chain solutions for the life sciences, today announced the unveiling of MVE Biological Solutions' ("MVE") integrated Condition Monitoring Solutions for its MVE SC 4/2 V and 4/3 V series dewars, both powered by Tec4Med, another Cryoport company. This launch reflects MVE's commitment to support the life sciences with intelligent, connected assets to safeguard vital commodities.

Combining MVE's trusted cryogenic systems with advanced condition monitoring technology, the new monitoring and visibility systems integrate either a SmartTagTM or CryoBeaconTM, built directly into dewar lids, to provide centralized condition monitoring. All collected data is managed within the MVECloudTM, a secure web- and mobile-based FDA 21 CFR Part 11, GAMP 5 compliant platform that provides visibility, real time alerts, and reporting on the cryogenic environment in which commodities are stored.

The CryoBeacon is a long-range Bluetooth Low Energy (BLE) 5.0 device that logs internal temperatures as low as –200°C, along with ambient temperature and humidity. Users can instantly retrieve data by scanning a QR code, making it easy to monitor both shipments and stationary storage equipment. The MVE SmartTag is a real-time condition-monitoring device with Long Term Evolution (LTE) connectivity and up to 120 days of battery life. It provides continuous visibility and alerts during transport or storage.

"We've integrated monitoring technology directly into our dewars so customers can manage their critical biological materials with confidence," said Mike Duich, President and CEO of MVE. "SmartTag and CryoBeacon not only simplify monitoring and reporting but empower our customers with the visibility and control they've been asking for. SmartTag and CryoBeacon are just the beginning as we move towards an exciting future where every MVE product is smart, connected, and designed to give our customers an increasingly greater peace of mind."

Jerrell Shelton, Chairman & CEO of Cryoport, added, "By introducing SmartTag and CryoBeacon, powered by Tec4med, MVE is further extending its market-leading position utilizing advanced technology and integrated monitoring solutions that enable it to enter into services and generate subscription-based revenue. This development by MVE aligns with Cryoport's broader strategy to equip customers with advanced tools that help manage their sensitive and valuable biological materials and lays the foundation for more connected, comprehensive monitoring and visibility solutions in the future."

About Cryoport, Inc.

Cryoport, Inc.  (Nasdaq: CYRX), is a leading global provider of temperature-controlled supply chain solutions for the Life Sciences, with an emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled supply chain for the Life Sciences. Our integrated supply chain platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, cryopreservation services, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands of the life sciences. With innovation, regulatory compliance, and agility at our core, we are "Enabling the Future of Medicine™." 

Headquartered in Nashville, Tennessee, our company maintains a strong global presence with operations across the Americas, EMEA, and APAC.

For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at  https://x.com/cryoport for live updates.

Forward-Looking Statements

Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/mve-biological-solutions-a-cryoport-company-introduces-real-time-integrated-condition-monitoring-systems-for-cryogenic-dewars-302576688.html

SOURCE Cryoport, Inc.

FAQ

What did MVE Biological Solutions announce on Oct 7, 2025 for CYRX?

MVE announced integrated real-time condition monitoring for MVE SC 4/2 V and 4/3 V dewars using SmartTag and CryoBeacon with data managed in MVECloud.

How does the CryoBeacon in MVE dewars monitor temperatures for CYRX products?

CryoBeacon is a BLE 5.0 device that logs internal temperatures down to –200°C and records ambient temperature and humidity.

What connectivity and battery life does the MVE SmartTag offer for CYRX monitoring?

SmartTag uses LTE connectivity and provides continuous visibility with up to 120 days of battery life.

Is MVECloud compliant with regulatory standards for CYRX customers?

Yes. MVECloud is described as FDA 21 CFR Part 11 and GAMP 5 compliant for secure web- and mobile-based data, alerts, and reporting.

Can users access monitoring data for MVE dewars in the field?

Yes. Users can retrieve data instantly by scanning a QR code and receive real-time alerts via MVECloud for both shipments and stationary storage.

What commercial impact did Cryoport say the MVE monitoring launch could have for CYRX?

Cryoport indicated the integrated monitoring could enable entry into services and support subscription-based revenue as part of its broader strategy.
Cryoport Inc

NASDAQ:CYRX

CYRX Rankings

CYRX Latest News

CYRX Latest SEC Filings

CYRX Stock Data

499.67M
47.31M
3.82%
100.71%
5.44%
Integrated Freight & Logistics
Pharmaceutical Preparations
Link
United States
BRENTWOOD